title: Micafungin: an evidence-based review of its place in therapy.
abstract: Invasive fungal infections have increased throughout the world. Many of these infections occur in patients with multiple comorbidities who are receiving medications with the potential for interactions with antifungal therapy that could lead to renal and hepatic dysfunction. The second marketed echinocandin, micafungin, was approved in 2005 for the treatment of esophageal candidiasis and prophylaxis of invasive Candida infections in patients undergoing hematopoietic stem cell transplantation. The indication for use was later expanded to include candidemia, acute disseminated candidiasis, Candida abscesses, and peritonitis. Like other echinocandins it is fungicidal against Candida species, including those that are polyene- and azole-resistant and fungistatic against Aspergillus species. Its formulation is by the intravenous route only and it is dosed once daily without a loading dose as 85% of the steady state concentration is achieved after three daily doses. It has a favorable tolerability profile with no significant drug interactions and does not need adjustment for renal or hepatic insufficiency.
authors.affiliation: Cooper Medical School of Rowan University, Camden, NJ, USA.
authors.forename: Pola
authors.initials: P
authors.lastname: de la Torre
authors.affiliation: Cooper Medical School of Rowan University, Camden, NJ, USA.
authors.forename: Annette C
authors.initials: AC
authors.lastname: Reboli
keywords: Aspergillus; Candida; echinocandin; micafungin; prophylaxis